Biomarkers in vasculitis

Current Opinion in Rheumatology

Volumn 26, Issue 1, 2014, Pages 24-30

  Monach, Paul A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

arteritis; biomarkers; vasculitis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE; COMPLEMENT COMPONENT C4; CRYOGLOBULIN; CXCL13 CHEMOKINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYTOKINE; DOUBLE STRANDED DNA ANTIBODY; EOTAXIN 3; FILAMIN; FILAMIN C; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G4; MEPRIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PENTRAXIN 3; PROTEIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANCA ASSOCIATED VASCULITIS; AORTA ARCH SYNDROME; ASTHMA; BLOOD VESSEL BIOPSY; BRAIN VASCULITIS; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CHURG STRAUSS SYNDROME; CRYOGLOBULINEMIA; CRYOGLOBULINEMIC VASCULITIS; DISEASE ACTIVITY; DISEASE SEVERITY; ECHOGRAPHY; EOSINOPHIL COUNT; EOSINOPHILIC GRANULOMA; ERYTHROCYTE SEDIMENTATION RATE; GIANT CELL ARTERITIS; HISTOPATHOLOGY; HUMAN; HYPEREOSINOPHILIC SYNDROME; MAGNETIC RESONANCE ANGIOGRAPHY; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POLYARTERITIS NODOSA; POSITRON EMISSION TOMOGRAPHY; PRIMARY ANGIITIS OF THE CENTRAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TEMPORAL ARTERY BIOPSY; TH2 CELL; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BIOLOGICAL MARKERS; GIANT CELL ARTERITIS; HUMANS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PROGNOSIS; TAKAYASU ARTERITIS; VASCULITIS;

EID: 84890224583     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000009     Document Type: Review

References (55)

1. Tomasson G, Lavalley M, Tanriverdi K, et al. Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. J Rheumatol 2011; 38:1048-1054.
2. Kalsch AI, Csernok E, Munch D, et al. Use of highly sensitive C-reactive protein for followupofWegener's granulomatosis. J Rheumatol2010; 37:2319-2325.
3. Monach PA, Warner RL, Tomasson G, et al. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCAassociated vasculitis. Ann Rheum Dis 2012; 72:1342-1350.
4. Magrey MN, Villa-Forte A, Koening CL, et al. Persistent hematuria after induction of remission in Wegener granulomatosis: A therapeutic dilemma. Medicine (Baltimore) 2009; 88:315-321.
5. Lieberthal JG, Cuthbertson D, Carette S, et al. urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol 2013; 40:674-683.
6. Haubitz M, Good DM, Woywodt A, et al. Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in antineutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics 2009; 8:2296-2307.
7. Tam FW, Sanders JS, George A, et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant 2004; 19:2761-2768.
8. Baerlecken NT, Linnemann A, Gross WL, et al. Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis 2012; 71:943-947.
9. Baldini M, Maugeri N, Ramirez GA, et al. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia. Arthritis Rheum 2012; 64:854-865.
10. Visvanathan S, Rahman MU, Hoffman GS, et al. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis: A prospective longitudinal study. Rheumatology (Oxford) 2011; 50:2061-2070.
11. Lozano E, Segarra M, Garcia-Martinez A, et al. New therapeutic targets in giant-cell arteritis: Considerations based on the current pathogenic model and the availability of new therapeutic agents. Clin Exp Rheumatol 2008; 26:S141-150.
12. Corbera-Bellalta M, Garcia-Martinez A, Lozano E, et al. Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: A new model for preclinical studies in giant-cell arteritis. Ann Rheum Dis 2013. [Epub ahead of print]
13. Brack A, Rittner HL, Younge BR, et al. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 1997; 99:2842-2850.
14. Piggott K, Deng J, Warrington K, et al. Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. Circulation 2011; 123:309- 318.
15. Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: Angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003; 107:2428-2434.
16. Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of proinflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004; 43:294-301.
17. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med 1994; 120:919-929.
18. Sun Y, Ma L, Yan F, et al. MMP-9 and IL-6 are potential biomarkers for disease activity in Takayasu's arteritis. Int J Cardiol 2012; 156:236-238.
19. Mahajan N, Dhawan V, Malik S, Jain S. Serum levels of soluble receptor for advanced glycation end products (sRAGE) in Takayasu's arteritis. Int J Cardiol 2010; 145:589-591.
20. Matsuyama A, Sakai N, Ishigami M, et al. Matrix metalloproteinases as novel disease markers in Takayasu arteritis. Circulation 2003; 108:1469-1473.
21. Dagna L, Salvo F, Tiraboschi M, et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011; 155:425-433.
22. Muller B, Peri G, Doni A, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001; 29:1404-1407.
23. Uusitalo-Seppala R, Huttunen R, Aittoniemi J, et al. Pentraxin 3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection: A prospective cohort study. PLoS One 2013; 8:e53661.
24. Ishihara T, Haraguchi G, Kamiishi T, et al. Sensitive assessment of activity of Takayasu's arteritis by pentraxin3, a new biomarker. J Am Coll Cardiol 2011; 57:1712-1713.
25. Takeuchi S, Kimura S, Soma Y, et al. Lysosomal-associated membrane protein-2 plays an important role in the pathogenesis of primary cutaneous vasculitis. Rheumatology (Oxford) 2013; 52:1592-1598.
26. Cellucci T, Tyrrell PN, Pullenayegum E, Benseler SM. von Willebrand factor antigen: A possible biomarker of disease activity in childhood central nervous system vasculitis? Rheumatology (Oxford) 2012; 51:1838-1845.
27. Polzer K, Karonitsch T, Neumann T, et al. Eotaxin-3 is involved in Churg- Strauss syndrome: A serum marker closely correlating with disease activity. Rheumatology (Oxford) 2008; 47:804-808.
28. Zwerina J, Bach C, Martorana D, et al. Eotaxin-3 in Churg-Strauss syndrome: A clinical and immunogenetic study. Rheumatology (Oxford) 2011; 50:1823- 1827.
29. Vaglio A, Strehl JD, Manger B, et al. IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis 2012; 71:390-393.
30. Dallos T, Heiland GR, Strehl J, et al. CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum 2010; 62:3496- 3503.
31. Szczeklik W, Sanak M, Mastalerz L, et al. 12-hydroxy-eicosatetraenoic acid (12-HETE): A biomarker of Churg-Strauss syndrome. Clin Exp Allergy 2012; 42:513-522.
32. Monach PA, Kumpers P, Lukasz A, et al. Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis. PLoS One 2012; 7:e30197.
33. Monach PA, Tomasson G, Specks U, et al. Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2011; 63:3988-3997.
34. Wibisono D, Csernok E, Lamprecht P, et al. Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis. Ann Rheum Dis 2010; 69:1888-1889.
35. Henes FO, Chen Y, Bley TA, et al. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis 2011; 70:1926-1929.
36. Takakuwa Y, Kurokawa MS, Ooka S, et al. AC13, a C-terminal fragment of apolipoprotein A-I, is a candidate biomarker for microscopic polyangiitis. Arthritis Rheum 2011; 63:3613-3624.
37. Pepper RJ, Hamour S, Chavele KM, et al. Leukocyte and serum S100A8/ S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. Kidney Int 2013; 83:1150-1158.
38. Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up. Ann Rheum Dis 2011; 71:955-960.
39. Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. Arthritis Rheum 2008; 58:2908-2918.
40. Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, et al. Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford) 2010; 49:2181-2190.
41. McKinney EF, Lyons PA, Carr EJ, et al. A CD8 T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 2010; 16:586-591; 581p following 591.
42. Saadoun D, Resche Rigon M, Thibault V, et al. Peg-IFNalpha/ribavirin/pro tease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: Results at week 24. Ann Rheum Dis 2013. [Epub ahead of print]
43. Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: Data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken) 2010; 62:1787-1795.
44. Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature. Autoimmun Rev 2011; 11:48-55.
45. Antonelli A, Fallahi P, Ferrari SM, et al. Chemokine (CXC motif) ligand 9 serum levels in mixed cryoglobulinaemia are associated with circulating levels of IFN-gamma and TNF-alpha. Clin Exp Rheumatol 2012; 30:864-870.
46. Antonelli A, Fallahi P, Ferrari SM, et al. Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis. Mod Rheumatol 2012; 22:659-667.
47. Antonelli A, Ferri C, Ferrari SM, et al. High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia. Clin Rheumatol 2009; 28:1179-1185.
48. Antonelli A, Ferri C, Ferrari SM, et al. Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. J Rheumatol 2010; 37:91-97.
49. Sansonno D, Tucci FA, Troiani L, et al. Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis. Blood 2008; 112:1620-1627.
50. Landau DA, Saadoun D, Halfon P, et al. Relapse of hepatitis C virusassociated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008; 58:604-611.
51. Dahdah N, Siles A, Fournier A, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 2009; 30:810-817.
52. McNeal-Davidson A, Fournier A, Spigelblatt L, et al. Value of amino-terminal pro B-natriuretic peptide in diagnosing Kawasaki disease. Pediatr Int 2012; 54:627-633.
53. Kentsis A, Shulman A, Ahmed S, et al. Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease. EMBO Mol Med 2013; 5:210-220.
54. Chen J, Liu Y, Liu W, Wu Z. A meta-analysis of the biomarkers associated with coronary artery lesions secondary to Kawasaki disease in Chinese children. J Huazhong Univ Sci Technolog Med Sci 2011; 31:705-711.
55. Kaneko K, Yoshimura K, Ohashi A, et al. Prediction of the risk of coronary arterial lesions in Kawasaki disease by brain natriuretic peptide. Pediatr Cardiol 2011; 32:1106-1109.